UBS Group
LPCN icon

UBS Group’s Lipocine LPCN Stock Holding History

UBS Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.9K Sell
3,494
-2,109
-38% -$18.4K ﹤0.01% 7735
2025
Q4 		$45K Buy
5,603
+3,837
+217% +$12.9K ﹤0.01% 7284
2025
Q3 		$5.03K Buy
1,766
+1,291
+272% +$3.92K ﹤0.01% 8906
2025
Q2 		$1.5K Buy
475
+276
+139% +$896 ﹤0.01% 9611
2025
Q1 		$632 Buy
199
+196
+6,533% +$759 ﹤0.01% 9704
2024
Q4 		$15 Sell
3
-59,410
-100% -$302K ﹤0.01% 9792
2024
Q3 		$267K Buy
59,413
+3,192
+6% +$16K ﹤0.01% 5660
2024
Q2 		$463K Buy
56,221
+55,790
+12,944% +$349K ﹤0.01% 5061
2024
Q1 		$2.24K Buy
+431
New +$1.68K ﹤0.01% 7949
2023
Q4 		– Sell
-42
Closed -$125 – 9646
2023
Q3 		$125 Buy
+42
New +$177 ﹤0.01% 8831
2023
Q2 		– Sell
-1,477
Closed -$7.99K – 9326
2023
Q1 		$7.99K Buy
1,477
+803
+119% +$6.2K ﹤0.01% 7763
2022
Q4 		$4.58K Buy
674
+645
+2,224% +$4.7K ﹤0.01% 9311
2022
Q3 		$0 Hold
29
– – ﹤0.01% 10671
2022
Q2 		$0 Sell
29
-404
-93% -$6.3K ﹤0.01% 10660
2022
Q1 		$10K Buy
433
+198
+84% +$4.14K ﹤0.01% 8420
2021
Q4 		$4K Buy
235
+113
+93% +$2.1K ﹤0.01% 9529
2021
Q3 		$2K Sell
122
-277
-69% -$6.11K ﹤0.01% 8964
2021
Q2 		$9K Buy
399
+281
+238% +$6.61K ﹤0.01% 8144
2021
Q1 		$3K Buy
118
+30
+34% +$866 ﹤0.01% 8521
2020
Q4 		$2K Hold
88
– – ﹤0.01% 8100
2020
Q3 		$2K Buy
88
+29
+49% +$770 ﹤0.01% 7667
2020
Q2 		$1K Sell
59
-134
-69% -$1.74K ﹤0.01% 7776
2020
Q1 		$1K Sell
193
-160
-45% -$1.27K ﹤0.01% 7774
2019
Q4 		$2K Buy
353
+294
+498% +$7.53K ﹤0.01% 7836
2019
Q3 		$3K Sell
59
-207
-78% -$8.31K ﹤0.01% 7641
2019
Q2 		$9K Buy
266
+76
+40% +$2.35K ﹤0.01% 7132
2019
Q1 		$7K Buy
+190
New +$5.83K ﹤0.01% 7010
2018
Q4 		– Sell
-403
Closed -$10K – 8179
2018
Q3 		$10K Buy
403
+253
+169% +$6.22K ﹤0.01% 7169
2018
Q2 		$4K Sell
150
-655
-81% -$15.6K ﹤0.01% 7555
2018
Q1 		$21K Buy
805
+645
+403% +$18K ﹤0.01% 6382
2017
Q4 		$10K Sell
160
-116
-42% -$7.21K ﹤0.01% 7022
2017
Q3 		$19K Buy
276
+265
+2,409% +$19.2K ﹤0.01% 6494
2017
Q2 		$1K Sell
11
-54
-83% -$3.52K ﹤0.01% 7500
2017
Q1 		$4K Sell
65
-89
-58% -$5.77K ﹤0.01% 7072
2016
Q4 		$10K Sell
154
-204
-57% -$12.9K ﹤0.01% 6923
2016
Q3 		$27K Buy
+358
New +$22.2K ﹤0.01% 6032
2016
Q2 		– Sell
-1,948
Closed -$336K – 7862
2016
Q1 		$336K Buy
1,948
+1,820
+1,422% +$311K ﹤0.01% 4093
2015
Q4 		$28K Buy
128
+108
+540% +$22.7K ﹤0.01% 6398
2015
Q3 		$4K Buy
+20
New +$4.63K ﹤0.01% 7822
2015
Q1 		– Sell
-21
Closed -$2K – 9095
2014
Q4 		$2K Buy
+21
New +$1.77K ﹤0.01% 9404

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

UBS Group's LPCN Position: Q1 2026 in Review

UBS Group reduced its Lipocine (LPCN) stake by 38% in Q1 2026, selling an estimated $18.4K and leaving 3,494 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7735.

UBS Group first reported a position in LPCN in Q4 2014 and has held it in 40 quarters since. The position peaked at $463K in Q2 2024. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • UBS Group held 3,494 shares of Lipocine worth $27.9K as of Q1 2026.
  • UBS Group sold 2,109 Lipocine shares in Q1 2026, an estimated $18.4K.
  • Lipocine made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7735 holding.
  • UBS Group first reported a position in Lipocine in Q4 2014 and has held it in 40 quarters since.
  • UBS Group's Lipocine position peaked at $463K in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.